CHILDREN'S ADVIL-FLAVORED (ibuprofen) by GSK is cyclooxygenase inhibitors [moa]. First approved in 1996.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
Children's Advil-Flavored is an oral ibuprofen suspension approved in 1996 for pediatric use, formulated to improve palatability and compliance in children. It is a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase enzymes to reduce pain, fever, and inflammation. The suspension dosage form and child-friendly flavoring make it a practical option for parents managing fever and minor aches in children.
Product is approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential team contraction or transition focus to line extensions or patient retention strategies.
Cyclooxygenase Inhibitors
Nonsteroidal Anti-inflammatory Drug
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Comparative Bioavailability Study of Reformulated Ibuprofen 2% and 4% Oral Suspensions (Berlin Chemie AG) and Versus Ibuprofen (Nurofen®) 200 mg/5 ml Oral Suspension
Efficacy and Safety of S (+) - Ibuprofen in Osteoarthritis Pain
Efficacy and Safety of S (+) - Ibuprofen in the Treatment of Mechanical Low Back Pain
Postoperative Analgesic Effects of Ibuprofen Versus Ketorolac in Patients Undergoing in Orthopedic Surgery
Ibuprofen Plus Acetaminophen for Enhanced Pain Reduction
Worked on CHILDREN'S ADVIL-FLAVORED at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on Children's Advil-Flavored offers stable, entry-to-mid-level career opportunities in consumer health and OTC brand management with established playbooks and minimal innovation risk. However, the approaching LOE and mature competitive landscape limit upside growth potential and may result in smaller team sizes compared to newer brands.